

MEDTRONIC, INC.
WORLD WIDE REVENUE
(Unaudited)

(\$ millions)

	FY11 QTR 1	FY11 QTR 2	FY11 QTR 3	FY11 QTR 4	FY11 Total	FY12 QTR 1	FY12 QTR 2	FY12 QTR 3	FY12 QTR 4	FY12 Total
REPORTED REVENUE :										
CARDIAC RHYTHM DISEASE MANAGEMENT	\$ 1,226	\$ 1,248	\$ 1,221	\$ 1,315	\$ 5,010	\$ 1,253	\$ -	\$ -	\$ -	\$ 1,253
Pacing Systems	473	472	450	506	1,901	508	-	-	-	508
Defibrillation Systems	722	745	735	760	2,962	697	-	-	-	697
AF & Other	31	31	36	49	147	48	-	-	-	48
CARDIOVASCULAR	\$ 717	\$ 738	\$ 774	\$ 879	\$ 3,109	\$ 850	\$ -	\$ -	\$ -	\$ 850
Coronary	342	350	370	404	1,466	389	-	-	-	389
Structural Heart	224	237	241	274	977	275	-	-	-	275
Endovascular & Peripheral	151	151	163	201	666	186	-	-	-	186
PHYSIO-CONTROL	\$ 84	\$ 109	\$ 104	\$ 128	\$ 425	\$ 103	\$ -	\$ -	\$ -	\$ 103
CARDIAC & VASCULAR GROUP	\$ 2,027	\$ 2,095	\$ 2,099	\$ 2,322	\$ 8,544	\$ 2,206	\$ -	\$ -	\$ -	\$ 2,206
SPINAL	\$ 829	\$ 850	\$ 861	\$ 875	\$ 3,414	\$ 825	\$ -	\$ -	\$ -	\$ 825
Core Spinal	622	634	626	648	2,530	610	-	-	-	610
Biologics	207	216	235	227	884	215	-	-	-	215
NEUROMODULATION	\$ 370	\$ 388	\$ 401	\$ 432	\$ 1,592	\$ 397	\$ -	\$ -	\$ -	\$ 397
DIABETES	\$ 312	\$ 326	\$ 341	\$ 368	\$ 1,347	\$ 355	\$ -	\$ -	\$ -	\$ 355
SURGICAL TECHNOLOGIES	\$ 235	\$ 244	\$ 259	\$ 298	\$ 1,036	\$ 266	\$ -	\$ -	\$ -	\$ 266
RESTORATIVE THERAPIES GROUP	\$ 1,746	\$ 1,808	\$ 1,862	\$ 1,973	\$ 7,389	\$ 1,843	\$ -	\$ -	\$ -	\$ 1,843
TOTAL	\$ 3,773	\$ 3,903	\$ 3,961	\$ 4,295	\$ 15,933	\$ 4,049	\$ -	\$ -	\$ -	\$ 4,049
ADJUSTMENTS :										
CURRENCY IMPACT (1)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 186	\$ -	\$ -	\$ -	\$ 186
COMPARABLE OPERATIONS (1)	\$ 3,773	\$ 3,903	\$ 3,961	\$ 4,295	\$ 15,933	\$ 3,863	\$ -	\$ -	\$ -	\$ 3,863

(1) Medtronic management believes that in order to properly understand Medtronic's short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on revenue. In addition, Medtronic management uses results of operations before currency translation to evaluate the operational performance of the Company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.

Note: The data in this schedule has been intentionally rounded to the nearest million and therefore the quarterly revenue may not sum to the fiscal year to date revenue.

MEDTRONIC, INC.
U.S. REVENUE
(Unaudited)

(\$ millions)

	FY11 QTR 1	FY11 QTR 2	FY11 QTR 3	FY11 QTR 4	FY11 Total	FY12 QTR 1	FY12 QTR 2	FY12 QTR 3	FY12 QTR 4	FY12 Total
REPORTED REVENUE :										
CARDIAC RHYTHM DISEASE MANAGEMENT	\$ 691	\$ 699	\$ 651	\$ 650	\$ 2,690	\$ 649	\$ -	\$ -	\$ -	\$ 649
Pacing Systems	214	210	182	207	812	217	-	-	-	217
Defibrillation Systems	467	481	458	425	1,831	411	-	-	-	411
AF & Other	10	8	11	18	47	21	-	-	-	21
CARDIOVASCULAR	\$ 241	\$ 248	\$ 249	\$ 289	\$ 1,026	\$ 266	\$ -	\$ -	\$ -	\$ 266
Coronary	92	96	94	101	382	90	-	-	-	90
Structural Heart	89	91	92	101	373	100	-	-	-	100
Endovascular & Peripheral	60	61	63	87	271	76	-	-	-	76
PHYSIO-CONTROL	\$ 53	\$ 64	\$ 56	\$ 74	\$ 248	\$ 60	\$ -	\$ -	\$ -	\$ 60
CARDIAC & VASCULAR GROUP	\$ 985	\$ 1,011	\$ 956	\$ 1,013	\$ 3,964	\$ 975	\$ -	\$ -	\$ -	\$ 975
SPINAL	\$ 631	\$ 645	\$ 646	\$ 631	\$ 2,553	\$ 589	\$ -	\$ -	\$ -	\$ 589
Core Spinal	439	445	431	429	1,744	398	-	-	-	398
Biologics	192	200	215	202	809	191	-	-	-	191
NEUROMODULATION	\$ 261	\$ 278	\$ 282	\$ 286	\$ 1,108	\$ 272	\$ -	\$ -	\$ -	\$ 272
DIABETES	\$ 203	\$ 213	\$ 219	\$ 228	\$ 863	\$ 214	\$ -	\$ -	\$ -	\$ 214
SURGICAL TECHNOLOGIES	\$ 149	\$ 148	\$ 156	\$ 179	\$ 632	\$ 156	\$ -	\$ -	\$ -	\$ 156
RESTORATIVE THERAPIES GROUP	\$ 1,244	\$ 1,284	\$ 1,303	\$ 1,324	\$ 5,156	\$ 1,231	\$ -	\$ -	\$ -	\$ 1,231
TOTAL	\$ 2,229	\$ 2,295	\$ 2,259	\$ 2,337	\$ 9,120	\$ 2,206	\$ -	\$ -	\$ -	\$ 2,206
ADJUSTMENTS :										
CURRENCY IMPACT	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
COMPARABLE OPERATIONS	\$ 2,229	\$ 2,295	\$ 2,259	\$ 2,337	\$ 9,120	\$ 2,206	\$ -	\$ -	\$ -	\$ 2,206

Note: The data in this schedule has been intentionally rounded to the nearest million and therefore the quarterly revenues may not sum to the fiscal year to date revenue.

MEDTRONIC, INC.
INTERNATIONAL REVENUE
(Unaudited)

(\$ millions)

	FY11 QTR 1	FY11 QTR 2	FY11 QTR 3	FY11 QTR 4	FY11 Total	FY12 QTR 1	FY12 QTR 2	FY12 QTR 3	FY12 QTR 4	FY12 Total
REPORTED REVENUE :										
CARDIAC RHYTHM DISEASE MANAGEMENT	\$ 535	\$ 549	\$ 570	\$ 665	\$ 2,320	\$ 604	\$ -	\$ -	\$ -	\$ 604
Pacing Systems	259	262	268	299	1,089	291	-	-	-	291
Defibrillation Systems	255	264	277	335	1,131	286	-	-	-	286
AF & Other	21	23	25	31	100	27	-	-	-	27
CARDIOVASCULAR	\$ 476	\$ 490	\$ 525	\$ 590	\$ 2,083	\$ 584	\$ -	\$ -	\$ -	\$ 584
Coronary	250	254	276	303	1,084	299	-	-	-	299
Structural Heart	135	146	149	173	604	175	-	-	-	175
Endovascular & Peripheral	91	90	100	114	395	110	-	-	-	110
PHYSIO-CONTROL	\$ 31	\$ 45	\$ 48	\$ 54	\$ 177	\$ 43	\$ -	\$ -	\$ -	\$ 43
CARDIAC & VASCULAR GROUP	\$ 1,042	\$ 1,084	\$ 1,143	\$ 1,309	\$ 4,580	\$ 1,231	\$ -	\$ -	\$ -	\$ 1,231
SPINAL	\$ 198	\$ 205	\$ 215	\$ 244	\$ 861	\$ 236	\$ -	\$ -	\$ -	\$ 236
Core Spinal	183	189	195	219	786	212	-	-	-	212
Biologics	15	16	20	25	75	24	-	-	-	24
NEUROMODULATION	\$ 109	\$ 110	\$ 119	\$ 146	\$ 484	\$ 125	\$ -	\$ -	\$ -	\$ 125
DIABETES	\$ 109	\$ 113	\$ 122	\$ 140	\$ 484	\$ 141	\$ -	\$ -	\$ -	\$ 141
SURGICAL TECHNOLOGIES	\$ 86	\$ 96	\$ 103	\$ 119	\$ 404	\$ 110	\$ -	\$ -	\$ -	\$ 110
RESTORATIVE THERAPIES GROUP	\$ 502	\$ 524	\$ 559	\$ 649	\$ 2,233	\$ 612	\$ -	\$ -	\$ -	\$ 612
TOTAL	\$ 1,544	\$ 1,608	\$ 1,702	\$ 1,958	\$ 6,813	\$ 1,843	\$ -	\$ -	\$ -	\$ 1,843
ADJUSTMENTS :										
CURRENCY IMPACT (1)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 186	\$ -	\$ -	\$ -	\$ 186
COMPARABLE OPERATIONS (1)	\$ 1,544	\$ 1,608	\$ 1,702	\$ 1,958	\$ 6,813	\$ 1,657	\$ -	\$ -	\$ -	\$ 1,657

(1) Medtronic management believes that in order to properly understand Medtronic's short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on revenue. In addition, Medtronic management uses results of operations before currency translation to evaluate the operational performance of the Company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.

Note: The data in this schedule has been intentionally rounded to the nearest million and therefore the quarterly revenue may not sum to the fiscal year to date revenue.

MEDTRONIC, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited)

	Three months ended	
	July 29, 2011	July 30, 2010
	(in millions, except per share data)	
Net sales	\$ 4,049	\$ 3,773
Costs and expenses:		
Cost of products sold	1,006	893
Research and development expense	371	370
Selling, general, and administrative expense	1,408	1,334
Acquisition-related items	13	15
Amortization of intangible assets	88	82
Other expense (income)	109	(35)
Interest expense, net	32	74
Total costs and expenses	<u>3,027</u>	<u>2,733</u>
Earnings before income taxes	1,022	1,040
Provision for income taxes	<u>201</u>	<u>210</u>
Net earnings	<u>\$ 821</u>	<u>\$ 830</u>
Basic earnings per share	<u>\$ 0.77</u>	<u>\$ 0.76</u>
Diluted earnings per share	<u>\$ 0.77</u>	<u>\$ 0.76</u>
Basic weighted average shares outstanding	1,063.5	1,086.1
Diluted weighted average shares outstanding	1,069.6	1,089.7
Cash dividends declared per common share	\$ 0.2425	\$ 0.2250

MEDTRONIC, INC.
RECONCILIATION OF CONSOLIDATED GAAP NET EARNINGS
TO CONSOLIDATED NON-GAAP NET EARNINGS
(Unaudited)
(in millions, except per share data)

	<u>Three months ended</u>		<u>Percentage Change</u>
	<u>July 29, 2011</u>	<u>July 30, 2010</u>	
Net earnings, as reported	\$ 821	\$ 830	-1%
Acquisition-related items	11 (a)	11 (c)	
Impact of authoritative convertible debt guidance on interest expense, net	13 (b)	27 (b)	
Non-GAAP net earnings	<u>\$ 845</u>	<u>\$ 868</u>	-3%

MEDTRONIC, INC.
RECONCILIATION OF CONSOLIDATED GAAP DILUTED EPS
TO CONSOLIDATED NON-GAAP DILUTED EPS
(Unaudited)

	<u>Three months ended</u>		<u>Percentage Change</u>
	<u>July 29, 2011</u>	<u>July 30, 2010</u>	
Diluted EPS, as reported	\$ 0.77	\$ 0.76	1%
Acquisition-related items	0.01 (a)	0.01 (c)	
Impact of authoritative convertible debt guidance on interest expense, net	0.01 (b)	0.02 (b)	
Non-GAAP diluted EPS	<u>\$ 0.79</u>	<u>\$ 0.80 (1)</u>	-1%

(1) The data in this schedule has been intentionally rounded to the nearest \$0.01 and therefore may not sum.

(a) The \$11 million (\$0.01 per share) after-tax (\$13 million pre-tax) acquisition-related items includes an \$8 million after-tax charge related to the change in fair value of contingent milestone payments associated with acquisitions subsequent to April 29, 2009, and \$3 million after-tax charge for transaction costs related to the potential divestiture of our Physio-Control business. In addition to disclosing acquisition-related items that are determined in accordance with U.S. generally accepted accounting principles (U.S. GAAP), Medtronic management believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding these acquisition-related items. Management believes that the resulting non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company's ongoing operations and is useful for period over period comparisons of such operations. Medtronic management eliminates these acquisition-related items when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP financial measure may not be the same or similar to measures presented by other companies.

(b) The Financial Accounting Standards Board (FASB) authoritative guidance for convertible debt accounting has resulted in an after-tax impact to net earnings of \$13 million (\$0.01 per share) and \$27 million (\$0.02 per share) for the three months ended July 29, 2011 and July 30, 2010, respectively. The pre-tax impact to interest expense, net was \$21 million and \$43 million for the three months ended July 29, 2011 and July 30, 2010, respectively. In addition to disclosing the financial statement impact of this authoritative guidance that is determined in accordance with U.S. GAAP, Medtronic management believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding the impact of this authoritative guidance. Management believes that the resulting non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company's ongoing operations and is useful for period over period comparisons of such operations. Medtronic management eliminates the impact of this authoritative guidance when evaluating the operating

performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP financial measure may not be the same as similar measures presented by other companies.

(c) The \$11 million (\$0.01 per share) after-tax (\$15 million pre-tax) acquisition-related items are related to a milestone payment under existing terms of a royalty bearing, non-exclusive patent cross-licensing agreement with NeuroPace, Inc. that the Company entered into in the first quarter of fiscal year 2006. This payment was charged to acquisition-related items as technological feasibility had not yet been reached and such technology had no future alternative use. In addition to disclosing acquisition-related items that are determined in accordance with U.S. GAAP, Medtronic management believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding these acquisition-related items. Management believes that the resulting non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company's ongoing operations and is useful for period over period comparisons of such operations. Medtronic management eliminates these acquisition-related items when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP financial measure may not be the same or similar to measures presented by other companies.

MEDTRONIC, INC.
RECONCILIATION OF WORLDWIDE REVENUE GROWTH TO CONSTANT CURRENCY GROWTH
(Unaudited)
(in millions)

	Three months ended		Reported Growth	Currency Impact on Growth (a)		Constant Currency Growth (a)
	July 29, 2011	July 30, 2010		Dollar	Percentage	
Reported Revenue:						
Pacing Systems	\$ 508	\$ 473	7 %	\$ 30	6 %	1 %
Defibrillation Systems	697	722	(3)	33	5	(8)
AF & Other	48	31	55	2	7	48
Cardiac Rhythm Disease Management	1,253	1,226	2	65	5	(3)
Coronary	389	342	14	26	8	6
Structural Heart	275	224	23	17	8	15
Endovascular & Peripheral	186	151	23	11	7	16
CardioVascular	850	717	19	54	8	11
Physio-Control	103	84	23	5	6	17
Cardiac & Vascular Group	2,206	2,027	9	124	6	3
Core Spinal	610	622	(2)	21	3	(5)
Biologics	215	207	4	3	2	2
Spinal	825	829	-	24	3	(3)
Neuromodulation	397	370	7	13	3	4
Diabetes	355	312	14	15	5	9
Surgical Technologies	266	235	13	10	4	9
Restorative Therapies Group	1,843	1,746	6	62	4	2
Total	\$ 4,049	\$ 3,773	7 %	\$ 186	5 %	2 %

(a) Medtronic management believes that in order to properly understand Medtronic's short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on revenue. In addition, Medtronic management uses results of operations before currency translation to evaluate the operational performance of the Company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with U.S. GAAP.

MEDTRONIC, INC.
RECONCILIATION OF INTERNATIONAL REVENUE GROWTH TO CONSTANT CURRENCY GROWTH
(Unaudited)
(in millions)

	Three months ended		Reported Growth	Currency Impact on Growth (a)		Constant Currency Growth (a)
	July 29, 2011	July 30, 2010		Dollar	Percentage	
Reported Revenue:						
Pacing Systems	\$ 291	\$ 259	12 %	\$ 30	11 %	1 %
Defibrillation Systems	286	255	12	33	13	(1)
AF & Other	27	21	29	2	10	19
Cardiac Rhythm Disease Management	604	535	13	65	12	1
Coronary	299	250	20	26	11	9
Structural Heart	175	135	30	17	13	17
Endovascular & Peripheral	110	91	21	11	12	9
CardioVascular	584	476	23	54	12	11
Physio-Control	43	31	39	5	16	23
Cardiac & Vascular Group	1,231	1,042	18	124	12	6
Core Spinal	212	183	16	21	12	4
Biologics	24	15	60	3	20	40
Spinal	236	198	19	24	12	7
Neuromodulation	125	109	15	13	12	3
Diabetes	141	109	29	15	13	16
Surgical Technologies	110	86	28	10	12	16
Restorative Therapies Group	612	502	22	62	12	10
Total	\$ 1,843	\$ 1,544	19 %	\$ 186	12 %	7 %

(a) Medtronic management believes that in order to properly understand Medtronic's short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on revenue. In addition, Medtronic management uses results of operations before currency translation to evaluate the operational performance of the Company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with U.S. GAAP.

MEDTRONIC, INC.
RECONCILIATION OF EMERGING MARKET REVENUE GROWTH TO CONSTANT CURRENCY GROWTH
(Unaudited)
(in millions)

	<u>Three months ended</u>		<u>Reported Growth</u>	<u>Currency Impact on Growth (a)</u>		<u>Constant Currency Growth (a)</u>
	<u>July 29, 2011</u>	<u>July 30, 2010</u>		<u>Dollar</u>	<u>Percentage</u>	
Emerging Market Revenue (b)	\$ 408	\$ 313	30 %	17	5 %	25 %

(a) Medtronic management believes that in order to properly understand Medtronic's short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on revenue. In addition, Medtronic management uses results of operations before currency translation to evaluate the operational performance of the Company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with U.S. GAAP.

(b) Emerging Market Revenue includes revenues from certain countries located in Central and Eastern Europe, Middle East, Africa, Latin America, and Asia.

MEDTRONIC, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

	July 29, 2011	April 29, 2011
(in millions, except per share data)		
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 1,393	\$ 1,382
Short-term investments	1,128	1,046
Accounts receivable, less allowances of \$100 and \$97, respectively	3,745	3,822
Inventories	1,808	1,695
Deferred tax assets, net	610	605
Prepaid expenses and other current assets	601	567
Total current assets	9,285	9,117
Property, plant, and equipment	5,939	5,817
Accumulated depreciation	(3,418)	(3,306)
Property, plant, and equipment, net	2,521	2,511
Goodwill	9,541	9,537
Other intangible assets, net	2,695	2,777
Long-term investments	6,655	6,120
Other assets	394	362
Total assets	\$ 31,091	\$ 30,424
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Short-term borrowings	\$ 1,857	\$ 1,723
Accounts payable	537	511
Accrued compensation	683	896
Accrued income taxes	184	50
Other accrued expenses	1,544	1,534
Total current liabilities	4,805	4,714
Long-term debt	8,195	8,112
Long-term accrued compensation and retirement benefits	489	480
Long-term accrued income taxes	566	496
Long-term deferred tax liabilities, net	279	220
Other long-term liabilities	417	434
Total liabilities	14,751	14,456
Commitments and contingencies		
Shareholders' equity:		
Preferred stock— par value \$1.00	-	-
Common stock— par value \$0.10	106	107
Retained earnings	16,319	16,085
Accumulated other comprehensive loss	(85)	(224)
Total shareholders' equity	16,340	15,968
Total liabilities and shareholders' equity	\$ 31,091	\$ 30,424

MEDTRONIC, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Three months ended	
	July 29, 2011	July 30, 2010
(in millions)		
Operating Activities:		
Net earnings	\$ 821	\$ 830
Adjustments to reconcile net earnings to net cash provided by operating activities:		
Depreciation and amortization	211	187
Amortization of discount on senior convertible notes	21	43
Acquisition-related items	8	15
Provision for doubtful accounts	7	5
Deferred income taxes	11	(22)
Stock-based compensation	41	49
Change in operating assets and liabilities, net of effect of acquisitions:		
Accounts receivable, net	67	63
Inventories	(94)	(73)
Accounts payable and accrued liabilities	(361)	(322)
Other operating assets and liabilities	383	30
Net cash provided by operating activities	1,115	805
Investing Activities:		
Acquisitions, net of cash acquired	(7)	(62)
Purchase of intellectual property	(1)	-
Additions to property, plant, and equipment	(130)	(108)
Purchases of marketable securities	(2,023)	(1,747)
Sales and maturities of marketable securities	1,602	1,183
Other investing activities, net	(38)	(55)
Net cash used in investing activities	(597)	(789)
Financing Activities:		
Change in short-term borrowings, net	128	816
Payments on long-term debt	-	(2)
Dividends to shareholders	(257)	(245)
Issuance of common stock	32	25
Repurchase of common stock	(400)	(640)
Net cash used in financing activities	(497)	(46)
Effect of exchange rate changes on cash and cash equivalents	(10)	(6)
Net change in cash and cash equivalents	11	(36)
Cash and cash equivalents at beginning of period	1,382	1,400
Cash and cash equivalents at end of period	\$ 1,393	\$ 1,364
Supplemental Cash Flow Information		
Cash paid for:		
Income taxes	\$ 9	\$ 261
Interest	30	60